Autres langues Xspray Pharma AB

Actions

XSPRAY

SE0009973563

Marché Fermé - Nasdaq Stockholm Autres places de cotation 17:13:08 26/04/2024			Varia. 5j.	Varia. 1 janv.
40,45 ^SEK	+0,50 %		+2,53 %	+1,12 %

14/02	Xspray Pharma AB (publ) annonce ses résultats pour le quatrième trimestre et l'exercice clos le 31 décembre 2023	CI
12/02	La FDA américaine accepte la nouvelle demande de Xspray Pharma pour un traitement potentiel de la leucémie	MT

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Xspray Pharma Announces Fourth Product Candidate, targeting USD 2.3 billion Market	22/04
Xspray Pharma receives declaration of intent from Östersjöstiftelsen regarding exercise of TO6 warrants	19/04
Important information to holders of warrants series TO6: subscription period begins today	18/04
Notice of annual general meeting of Xspray Pharma AB (publ)	18/04
Xspray Pharma receives declarations of intent from its largest owners regarding exercise of TO6 warrants	10/04
Xspray Pharma publishes its Annual Report 2023	27/03
Xspray Pharma Q4 2023 - NDA-resubmission accepted by the FDA	16/02
Interim Report Fourth Quarter 2023	14/02
Xspray Pharma AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	14/02
FDA Accepts Xspray Pharma's NDA-resubmission for Dasynoc, PDUFA Date set to 31 July	13/02
FDA Accepts Xspray Pharma’s NDA-resubmission for Dasynoc® – PDUFA Date set to 31 July 2024	12/02
US FDA Accepts Xspray Pharma's Refiled Application for Potential Leukemia Treatment	12/02
FDA Accepts Xpray Pharma’s NDA-resubmission for Dasynoc® – PDUFA Date set to 31 July	12/02
FDA Accepts Xpray Pharma's NDA-Resubmission for Dasynoc® - PDUFA	12/02
Xspray Pharma appoints Michael af Winklerfelt as acting CFO	07/02
Xspray Pharma AB Appoints Kerstin Hasselgren as Head of IR	07/02
Xspray Pharma AB Announces CFO Changes	07/02
New number of shares and votes in Xspray Pharma	29/12
Xspray Pharma raises SEK 92.3 million through warrants TO5	01/12
Xspray Pharma's XS003 Achieves Superior Bioavailability Milestone, Matching TASIGNA at Reduced Dosage	22/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Xspray Pharma AB

Actions

XSPRAY

SE0009973563

Autres langues

Filtres